PCN232 DIVERGENT HTA DECISIONS IN EUROPE FOR ONCOLOGY DRUGS GRANTED BREAKTHROUGH DESIGNATION
May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.353
https://www.valueinhealthjournal.com/article/S1098-3015(19)30545-5/fulltext
Section Title :
Section Order :
10002
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30545-5&doi=10.1016/j.jval.2019.04.353